Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM study of LY3884963 in frontotemporal dementia with GRN mutations
2022-502942-29-01Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of LY3884963 in Progranulin-Associated Frontotemporal Dementia (FTD-GRN), sponsored by Eli Lilly and Company. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Sirolimus-related safety measures and 5 more. Planned start Aug 2024; status: authorised.
02
Drugs
LY3884963
03
Conditions
Progranulin-Associated Frontotemporal Dementia (FTD-GRN)
Beyond the preview
Go deeper on 2022-502942-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502942-29-01.